title: [Reinterventions in anaplastic cancers and sarcomas of the thyroid gland].
abstract: In the years 1979-1988, operations were performed on 41 anaplastic carcinomas and 11 sarcomas of the thyroid gland. Out of these cases reoperation was indicated in 18 patients (34.6%): in 11 cases only a palliative tracheotomy could be done (group I), whilst in the remaining 7 patients surgical removal of the recurrent tumour was possible (group II). Analysis of group II patients revealed that the initial surgical intervention had been a macroscopically radical operation. The difference between the survival rates of both groups was highly significant (group I 64 days, group II 412 days mean survival). Despite the fatal prognosis of these highly malignant tumours, we conclude that reoperation for the removal of a recurrent tumour is advisable in those patients in whom the initial operation was a radical excision. Longer survival rates and improved quality of life were achieved. If the initial operation was merely palliative, then only a tracheotomy is the likely procedure in case of recurrence.
authors.affiliation: Chirurgische Abteilung, Kaiserin-Elisabeth-Spitals, Wien.
authors.forename: M
authors.initials: M
authors.lastname: Hermann
authors.forename: F
authors.initials: F
authors.lastname: Kober
authors.forename: C
authors.initials: C
authors.lastname: Hollinsky
authors.forename: A
authors.initials: A
authors.lastname: Heiss
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality; D012086:Reoperation; D012509:Sarcoma / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality / Q000601:surgery*; D013965:Thyroidectomy
vernacular_title: Reeingriffe bei anaplastischen Karzinomen und Sarkomen der Schilddrüse.